Mural Oncology (NASDAQ:MURA) Price Target Lowered to $6.00 at HC Wainwright

Mural Oncology (NASDAQ:MURA) had its target price dropped by equities researchers at HC Wainwright from $18.00 to $6.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 308.16% from the company’s current price.

Several other equities analysts have also commented on MURA. Jones Trading reaffirmed a “hold” rating on shares of Mural Oncology in a report on Tuesday. Morgan Stanley lowered Mural Oncology from an “overweight” rating to an “equal weight” rating in a report on Tuesday. Finally, Raymond James downgraded shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective for the company. in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $13.00.

Mural Oncology Stock Performance

Shares of Mural Oncology stock opened at $1.47 on Wednesday. Mural Oncology has a 1 year low of $1.37 and a 1 year high of $5.12. The firm’s 50-day simple moving average is $3.87 and its 200-day simple moving average is $3.61. The firm has a market cap of $25.33 million, a PE ratio of -0.16 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period in the prior year, the company posted ($3.57) EPS. On average, equities analysts predict that Mural Oncology will post -7.54 earnings per share for the current year.

Institutional Investors Weigh In On Mural Oncology

A number of institutional investors and hedge funds have recently modified their holdings of MURA. Commerce Bank acquired a new position in shares of Mural Oncology in the 3rd quarter worth $39,000. FMR LLC increased its stake in Mural Oncology by 124.7% in the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after purchasing an additional 11,423 shares in the last quarter. Jane Street Group LLC acquired a new stake in Mural Oncology during the 4th quarter worth about $68,000. Two Sigma Advisers LP purchased a new stake in Mural Oncology during the fourth quarter valued at about $84,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Mural Oncology in the fourth quarter worth about $94,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.